Quantbot Technologies LP Acquires Shares of 37,761 LivaNova PLC (NASDAQ:LIVN)

Quantbot Technologies LP purchased a new position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 37,761 shares of the company's stock, valued at approximately $1,984,000. Quantbot Technologies LP owned about 0.07% of LivaNova at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Point72 Asset Management L.P. increased its stake in LivaNova by 204.3% in the second quarter. Point72 Asset Management L.P. now owns 1,285,636 shares of the company's stock valued at $70,479,000 after purchasing an additional 863,157 shares during the last quarter. First Light Asset Management LLC grew its holdings in LivaNova by 591.1% in the 2nd quarter. First Light Asset Management LLC now owns 710,390 shares of the company's stock valued at $38,944,000 after buying an additional 607,598 shares during the period. Great Lakes Advisors LLC acquired a new position in shares of LivaNova during the 2nd quarter valued at about $16,614,000. Driehaus Capital Management LLC lifted its holdings in shares of LivaNova by 64.7% during the 2nd quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company's stock worth $29,824,000 after acquiring an additional 213,749 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its position in shares of LivaNova by 286.4% in the third quarter. The Manufacturers Life Insurance Company now owns 207,248 shares of the company's stock worth $10,889,000 after acquiring an additional 153,611 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently commented on LIVN shares. Needham & Company LLC reaffirmed a "buy" rating and set a $75.00 price target on shares of LivaNova in a research report on Monday. Baird R W upgraded LivaNova from a "hold" rating to a "strong-buy" rating in a report on Tuesday, September 17th. The Goldman Sachs Group started coverage on LivaNova in a report on Friday, October 4th. They issued a "buy" rating and a $65.00 target price on the stock. StockNews.com lowered LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Saturday, November 16th. Finally, Robert W. Baird raised their price objective on LivaNova from $66.00 to $72.00 and gave the stock an "outperform" rating in a report on Thursday, October 31st. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $69.17.

LivaNova Stock Up 0.0 %

NASDAQ:LIVN traded up $0.02 during mid-day trading on Friday, hitting $52.50. The company had a trading volume of 269,280 shares, compared to its average volume of 611,061. The business has a fifty day simple moving average of $52.24 and a 200-day simple moving average of $52.30. The firm has a market capitalization of $2.85 billion, a price-to-earnings ratio of 125.95 and a beta of 1.01. LivaNova PLC has a 1 year low of $42.75 and a 1 year high of $64.47. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.